Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) Market: Comprehensive study explores Huge Growth in Future

HTF MI Report, Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) – Drugs in Development, 2021, reveals the comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) – Drugs in Development, 2021, complete with analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type. Some of the Major Key Players Covered in this report are Actinogen Medical Ltd, Addex Therapeutics Ltd, Aision Biotechnologies Inc, Allied Corp, Alzamend Neuro Inc, Amorsa Therapeutics Inc, Anagin Inc, Ananda Scientific Inc, Aptinyx Inc, Artelo Biosciences Inc, Avicanna Inc, Bionomics Ltd, Bionorica SE, Bright Minds Biosciences Inc, Cannabis Science Inc, Champignon Brands Inc, Chronos Therapeutics Ltd, Corcept Therapeutics Inc, Delix Therapeutics Inc, Eli Lilly and Co, Embera NeuroTherapeutics Inc, EmpathBio, EpiVario Inc, Evecxia Therapeutics Inc, Exxel Pharma Inc, GW Pharmaceuticals Plc, H. Lundbeck AS, Immodulon Therapeutics Ltd, INVENT Pharmaceuticals Inc, Jazz Pharmaceuticals Plc, Johnson & Johnson, Kdac Therapeutics Inc, Lactocore Inc, Lixte Biotechnology Holdings Inc, Neuritek Therapeutics Ltd, NeuroNascent Inc, NeuroPharm Inc, NeuroRx Inc, Neurovation Labs Inc, Omeros Corp, One World Cannabis Ltd, Otsuka Pharmaceutical Co Ltd, Protagenic Therapeutics Inc, Psy Therapeutics Inc, PsyBio Therapeutics Corp, Quoin Pharmaceuticals Ltd, Sanofi, Scientus Pharma Inc, Seelos Therapeutics,  Inc., Synendos Therapeutics AG, Tonix Pharmaceuticals Holding Corp, VistaGen Therapeutics Inc.

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/3223483-post-traumatic-stress-disorder-7

Summary

HTF MI latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder – Drugs in Development, 2021, provides an overview of the Post-Traumatic Stress Disorder (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that’s triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

 

Report Highlights

HTF MI Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 1, 33, 11 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Post-Traumatic Stress Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (Central Nervous System)

 

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (Central Nervous System).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

Companies Mentioned in the Report

Actinogen Medical Ltd, Addex Therapeutics Ltd, Aision Biotechnologies Inc, Allied Corp, Alzamend Neuro Inc, Amorsa Therapeutics Inc, Anagin Inc, Ananda Scientific Inc, Aptinyx Inc, Artelo Biosciences Inc, Avicanna Inc, Bionomics Ltd, Bionorica SE, Bright Minds Biosciences Inc, Cannabis Science Inc, Champignon Brands Inc, Chronos Therapeutics Ltd, Corcept Therapeutics Inc, Delix Therapeutics Inc, Eli Lilly and Co, Embera NeuroTherapeutics Inc, EmpathBio, EpiVario Inc, Evecxia Therapeutics Inc, Exxel Pharma Inc, GW Pharmaceuticals Plc, H. Lundbeck AS, Immodulon Therapeutics Ltd, INVENT Pharmaceuticals Inc, Jazz Pharmaceuticals Plc, Johnson & Johnson, Kdac Therapeutics Inc, Lactocore Inc, Lixte Biotechnology Holdings Inc, Neuritek Therapeutics Ltd, NeuroNascent Inc, NeuroPharm Inc, NeuroRx Inc, Neurovation Labs Inc, Omeros Corp, One World Cannabis Ltd, Otsuka Pharmaceutical Co Ltd, Protagenic Therapeutics Inc, Psy Therapeutics Inc, PsyBio Therapeutics Corp, Quoin Pharmaceuticals Ltd, Sanofi, Scientus Pharma Inc, Seelos Therapeutics,  Inc., Synendos Therapeutics AG, Tonix Pharmaceuticals Holding Corp, VistaGen Therapeutics Inc.

Place a Purchase Order For Market Study (Single User License) at:  https://www.htfmarketreport.com/buy-now?format=1&report=3223483

Request a sample report @ https://www.htfmarketreport.com/sample-report/3223483-post-traumatic-stress-disorder-7

Table of Contents
Introduction
Post-Traumatic Stress Disorder (PTSD) – Overview
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment
Post-Traumatic Stress Disorder (PTSD) – Companies Involved in Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) – Drug Profiles
Post-Traumatic Stress Disorder (PTSD) – Dormant Projects
Post-Traumatic Stress Disorder (PTSD) – Discontinued Products
Post-Traumatic Stress Disorder (PTSD) – Product Development Milestones
AppendixList of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by C

….Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/3223483-post-traumatic-stress-disorder-7

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
[email protected]
Ph: +1 (206) 317 1218

https://testmeasurement.com.au/

Leave a Reply

Your email address will not be published. Required fields are marked *